로딩 중…
StockDiggingStockDigging

Bio-Techne Corporation

TECH· NASDAQ
$72.41+0.11%
2026-09-17

Financials

Valuation Metrics

Bio-Techne Corporation's Market Cap is $11.34B. At end of 2025 it was $9.15B. Ranked #858 of 3,121 in US market (top 27%), #269 of 1,463 on NASDAQ (top 18%), #42 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$11.34B
Revenue$1.22B
Net Income$182M
Total Assets$2.59B
Net Assets$2.11B
Employees3,100
Value
P/E62.34x
P/B5.38x
PEG0.42x
P/S9.33x
EV/EBITDA33.08x
FCF Yield2.32%
Profitability
ROE8.63%
ROA7.03%
Op. Margin20.73%
Revenue Growth-0.38%
Earnings Growth147.77%
Financial Health
Debt Ratio22.70%
Total Debt$289M
FCF$263M
Cash$265M
Current Ratio4.55x
Net Debt/EBITDA0.07x
Dividend
Div. Yield0.44%
Div. Growth0.06%
Performance
1Y Return40.93%
1M Return0.26%
From 52W High-0.29%
1Y MDD-39.26%
Trading
Volume3,737,451 shares
Trading Value$271M
Per Share
EPS$1.16
BPS$13.47

Company Info

CEO Mr. Kim Kelderman
Employees 3,100
HQ Minneapolis, United States

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.